Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck

Anti-Cancer Drugs

Volumn 15, Issue 4, 2004, Pages 331-340

  Pignon, Jean Pierre ^a   Syz, Nathalie ^a   Posner, Marshall ^b   Olivares, Robert ^c   Le Lann, Laurence ^c   Yver, Antoine ^c   Dunant, Ariane ^a   Lewin, Freddi ^d   Dalley, David N ^e   Paccagnella, Adriano ^f   Taylor, Samuel G ^g   Domenge, Christian ^a   Bourhis, Jean ^a   Mazumdar, Madhu ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SANOFI   (France)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e ST VINCENT S HOSPITAL   (Australia)

^f Divisione Medica I   (Italy)

^g ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cisplatin; Docetaxel; Head and neck cancer; Pooled analysis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID;

ACCURACY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STANDARDIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SQUAMOUS CELL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 11144355787     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200404000-00004     Document Type: Article

References (32)

1. Jacobs C. Head and neck cancer in 1994: a change in the standard of care. J Natl Cancer Inst 1994; 86:250-252.
2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355:949-955.
3. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000; 83:1594-1598.
4. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86:265-272.
5. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5:533-537.
6. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999; 81:457-462.
7. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14:1672-1678.
8. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16:1331-1339.
9. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17:3503-3511.
10. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002; 25:153-159.
11. Janinis J, Papadakou M, Xidakis E, Boukis H, Poulis A, Panagos G, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000; 23:128-131.
12. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19:1096-1104.
13. Posner MR, Vermoken JB, Janinis J, Bragas B, Yver A. Survival analysis of induction therapy with docetaxel (Taxotere) (T) containing regimens in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2001; 20:203 (abstr).
14. Cooper JS, Farnan NC, Asbell SO, Rotman M, Marcial V, Fu KK, et al. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 1996; 77:1905-1911.
15. Mazumdar M, Fazzari M, Panageas KS. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med 2001; 20:883-892.
16. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17:343-346.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 47:457-481.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
19. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39.
20. Cox DR. Regression models and life tables. J R Statist Soc 1972; 34:187-220.
21. Adelstein DJ, Sharan VM, Earle AS, Shah AC, Vlastou C, Haria CD, et al. Long-term follow-up of a prospective randomized trial comparing simultaneous and sequential chemoradiotherapy for squamous cell head and neck cancer. In: Salmon SE (editor): Adjuvant Therapy of Cancer VII. Philadelphia, PA: Lippincott; 1993, pp. 82-91.
22. Dalley D, Beller E, Aroney R, Dewar J, Page J, Phillip R, et al. The value of chemotherapy (CT) prior to definitive local therapy (DLT) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN). Proc Am Soc Clin Oncol 1995; 14:297 (abstr).
23. Depondt J, Gehanno P, Martin M, Lelievre G, Guerrier B, Peytral C, et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993; 50:23-27.
24. Di Blasio B, Barbieri W, Bozzetti A, Iotti C, DiSarra S, Cocconi G. A prospective randomized trial in resectable head and neck carcinoma: locoregional treatment with and without neoadjuvant chemotherapy. Proc Am Soc Clin Oncol 1994; 13:279 (abstr).
25. Gedouin D, Desprez P, Perron JJ, Fleury F, Leclech G, Miglianico L, et al. [Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment]. Bull Cancer Radiother 1996; 83:104-107 [in French].
26. Lewin F, Dambar L, Jonsson H, Andersson T, Berthelsen A, Biorklund A, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997; 43:23-28.
27. Martin M, Vergnes L, Lelièvre G. A randomized study of CDDP and 5-FU as neo-adjuvant chemotherapy in head and neck cancer: an interim analysis. In: Banzet P, Holland JF, Khayat D, Weil M (editors): Cancer Treatment: An Update. Paris: Springer-Verlag; 1994, pp. 214-218.
28. Taylor SG 4th, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation vs concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994; 12:385-395.
29. Tejedor M, Murias A, Sona P, Aguiar J, Salinas J, Hernandez MA, et al. Induction chemotherapy with carboplatin and ftoratur in advanced head and neck cancer. A randomized study. Am J Clin Oncol 1992; 15:417-421.
30. Fu KK. Combined-modality therapy for head and neck cancer. Oncology 1997; 11:1781-1796.
31. Bourhis J, Syz N, Overgaard J, Ang KK, Dische S, Horiot J, et al. Conventional vs modified fractionated radiotherapy. Meta-analysis of radiotherapy in head and neck carcinoma: a meta-analysis based on individual patient data. Int J Rad Oncol Biol Phys 2002; 54(suppl):71-72.
32. Dunn D, Babiker A, Hooker M, Darbyshire J. The dangers of inferring treatment effects from observational data: a case study in HIV infection. Control Clin Trials 2002; 23:106-110.